ImmunoGen, Inc. Announces Conference Call at 8:30 am ET October 11, 2010 to Discuss New Collaboration & Updated Guidance for ...
October 11 2010 - 5:15AM
Business Wire
ImmunoGen, Inc. (Nasdaq: IMGN), a biotechnology company that
develops targeted antibody-based anticancer products, today
announced that it will host a conference call at 8:30 am ET on
Monday, October 11, 2010 to discuss the Company's new collaboration
announced this morning and its updated financial guidance for
ImmunoGen’s fiscal year ending June 30, 2011.
To access the live call by phone, dial 913-312-0658. Passcode is
4078495. The call also may be accessed through the Investor
Information section of the Company's website, www.immunogen.com.
Following the live webcast, a replay of the call will be available
at the same location through October 18, 2010.
About ImmunoGen, Inc.
ImmunoGen, Inc. develops targeted anticancer therapeutics using
the Company’s expertise in tumor biology, monoclonal antibodies and
potent cancer-cell killing agents. The Company’s TAP technology
uses monoclonal antibodies to deliver one of ImmunoGen’s
proprietary cancer-cell killing agents specifically to tumor cells.
There are currently seven TAP compounds in the clinic, with a
wealth of clinical data reported with the technology. ImmunoGen
collaborative partners include Amgen, Bayer Schering Pharma, Biogen
Idec, Biotest, Genentech (a member of the Roche Group), Novartis,
and sanofi-aventis. The most advanced compound using ImmunoGen’s
TAP technology, T-DM1, is in Phase III testing through the
Company’s collaboration with Genentech. More information about
ImmunoGen can be found at www.immunogen.com.
ImmunoGen (NASDAQ:IMGN)
Historical Stock Chart
From Jun 2024 to Jul 2024
ImmunoGen (NASDAQ:IMGN)
Historical Stock Chart
From Jul 2023 to Jul 2024